EducationPhD University of Chicago, 2004 (Health Economics, Public Policy)
MS University of North Carolina (Chapel Hill), 1999 (Biostatistics)
MS University of Toledo, 1997 (Pharmaceutical Sciences)
BS Jadavpur University, 1995 (Pharmaceutical Sciences)
Contact Infoemail: email@example.com
web site: http://faculty.washington.edu/basua/
office: H-375Q, Health Sciences Building
Magnuson Health Sciences Center
1959 NE Pacific St.
Seattle, WA 98195-7630
campus box: 357630
Anirban Basu's work sits at the intersection of microeconomics, statistics, and health policy. His research focuses on comparative and cost effectiveness analyses, causal inference methods, program evaluation, and outcomes research.
Currently the Stergachis Family Endowed Professor and Director of the Pharmaceutical Outcomes Research and Policy Program at the University of Washington, Basu also serves as faculty member in the Department of Health Services and as an adjunct in the Department of Economics. Previously, Basu taught on the faculty of the University of Chicago Department of Medicine, where he remains an external affiliate of the Center for Health and the Social Sciences.
In addition to his position as a faculty research fellow at the National Bureau of Economic Research, Basu is as an associate editor for Health Economics, Journal of Health Economics, and Observational Studies, and has served as panelist or speaker at many economics and health studies conferences, nationally and abroad.
- HSERV 525
Advanced Health Services Research Methods III - Causal Inference Using Observational Data
Kim DD, Basu A. New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives. Med Decis Making. 2017 Apr 1:272989X17702379. doi: 10.1177/0272989X17702379. [Epub ahead of print] PMID: 28441507
Basu A, Coe NB. 2SLS vs 2SRI: Appropriate Methods for Rare Outcomes and/or Rare Exposures. Health Econ. 2017 Mar 5. doi: 10.1002/hec.3490. [Epub ahead of print] PMID: 28260248
Dhanda DS, Guzauskas GF, Carlson JJ, Basu A, Veenstra DL. Are evidence standards different for genomic- vs. clinical-based precision medicine? - A quantitative analysis of individualized warfarin therapy. Clin Pharmacol Ther. 2017 Feb 10. doi: 10.1002/cpt.663. [Epub ahead of print] PMID: 28187492
Yeung K, Basu A, Hansen RN, Watkins JB, Sullivan SD. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures. Med Care. 2017 Feb;55(2):191-198. doi: 10.1097/MLR.0000000000000630. PMID: 27579915
PI: Basu Dates: 6/1/2016 - 5/30/2017
PI: Basu Dates: 9/1/2015 - 8/31/2016
PI: Coe Dates: 7/1/2015 - 6/30/2019
PI: Veenstra Dates: 7/1/2015 - 6/30/2016
PI: Basu Dates: 6/1/2015 - 5/31/2016
PI: Flum Dates: 5/1/2015 - 4/30/2019
PI: Basu Dates: 9/1/2014 - 8/31/2015
PI: Veenstra Dates: 7/1/2014 - 6/30/2015
PI: Zatzick Dates: 7/1/2014 - 6/30/2019
PI: Basu Dates: 6/1/2014 - 5/31/2015
PI: Veenstra Dates: 10/1/2013 - 9/30/2018
PI: Carlson Dates: 6/1/2013 - 11/30/2015
PI: Basu Dates: 12/28/2011 - 8/31/2016
PI: Kessler Dates: 7/1/2011 - 6/30/2015
Comparative effectiveness research is a growing field that aims to generate evidence to improve health care decisions for patients and providers. It examines the benefits and risks of different medical or healthcare interventions, including drugs and medical technology. The results of these comparison studies are used by medical professionals to make better informed healthcare decisions and thereby improve patient care.
- Anirban Basu on panel that updated guide to caregiversâ€™ decisions
- UW Professors Named American Statistical Association Fellows
- Study Examines Outcomes, Costs after Return Visits to ER
- Outcomes from patient hospitalization after return visits to ER
- Drug projected at $1 million has spark mulling installment plan (Bloomberg Business, 08/06/2015)